Detail akcie GENOMED online

Business Summary: Genomed SA is a Poland-based company engaged in genetic research. It develops molecular diagnostics based on deoxyribonucleic acid (DNA) sequencing, with a special focus on the Next Generation Sequencing (NGS) method. The Company’s offer includes the analysis of gene mutations responsible for over 150 congenital diseases, such as infertility, predisposition to cancer, cystic fibrosis (CF), Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy and obesity, among others. The Company’s activities are directed toward introducing genomic technology to personalized medicine and creating a clinic offering gene treatments. The Company also provides diverse DNA sequencing, analysis and synthesis services for research and the biotechnological market.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, GENOMED SA revenues increased 10% to PLN22.5M. Net income increased from PLN338K to PLN992K. Revenues reflect Sale of Products increase of 12% to PLN22M. Net income benefited from Other Operating Expense decrease of 18% to PLN553K (expense), Depreciation & Amortization decrease of 14% to PLN619K (expense), Taxes and Fees decrease of 46% to PLN9K (expense).